Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

The cytotoxic natural product vioprolide A targets nucleolar protein 14 essential for ribosome biogenesis.

Kirsch VC, Orgler C, Braig S, Jeremias I, Auerbach D, Müller R, Vollmar AM, Sieber SA.

Angew Chem Int Ed Engl. 2019 Oct 28. doi: 10.1002/anie.201911158. [Epub ahead of print]

PMID:
31658409
2.

Neocarzilin A Is a Potent Inhibitor of Cancer Cell Motility Targeting VAT-1 Controlled Pathways.

Gleissner CM, Pyka CL, Heydenreuter W, Gronauer TF, Atzberger C, Korotkov VS, Cheng W, Hacker SM, Vollmar AM, Braig S, Sieber SA.

ACS Cent Sci. 2019 Jul 24;5(7):1170-1178. doi: 10.1021/acscentsci.9b00266. Epub 2019 Jun 18.

3.

Connecting lysosomes and mitochondria - a novel role for lipid metabolism in cancer cell death.

Bartel K, Pein H, Popper B, Schmitt S, Janaki-Raman S, Schulze A, Lengauer F, Koeberle A, Werz O, Zischka H, Müller R, Vollmar AM, von Schwarzenberg K.

Cell Commun Signal. 2019 Jul 29;17(1):87. doi: 10.1186/s12964-019-0399-2.

4.

Chivosazole A Modulates Protein-Protein Interactions of Actin.

Wang S, Gegenfurtner FA, Crevenna AH, Ziegenhain C, Kliesmete Z, Enard W, Müller R, Vollmar AM, Schneider S, Zahler S.

J Nat Prod. 2019 Jul 26;82(7):1961-1970. doi: 10.1021/acs.jnatprod.9b00335. Epub 2019 Jul 1.

PMID:
31260301
5.

Re-opening the stage for Echinacea research - Characterization of phylloxanthobilins as a novel anti-oxidative compound class in Echinacea purpurea.

Karg CA, Wang P, Vollmar AM, Moser S.

Phytomedicine. 2019 Jul;60:152969. doi: 10.1016/j.phymed.2019.152969. Epub 2019 May 22.

PMID:
31153733
6.

Targeting actin inhibits repair of doxorubicin-induced DNA damage: a novel therapeutic approach for combination therapy.

Pfitzer L, Moser C, Gegenfurtner F, Arner A, Foerster F, Atzberger C, Zisis T, Kubisch-Dohmen R, Busse J, Smith R, Timinszky G, Kalinina OV, Müller R, Wagner E, Vollmar AM, Zahler S.

Cell Death Dis. 2019 Apr 3;10(4):302. doi: 10.1038/s41419-019-1546-9.

7.

Combined antitumoral effects of pretubulysin and methotrexate.

Kern S, Truebenbach I, Höhn M, Gorges J, Kazmaier U, Zahler S, Vollmar AM, Wagner E.

Pharmacol Res Perspect. 2019 Jan 22;7(1):e00460. doi: 10.1002/prp2.460. eCollection 2019 Feb.

8.

A single-cell micro-trench platform for automatic monitoring of cell division and apoptosis after chemotherapeutic drug administration.

Chatzopoulou EI, Raharja-Liu P, Murschhauser A, Sekhavati F, Buggenthin F, Vollmar AM, Marr C, Rädler JO.

Sci Rep. 2018 Dec 21;8(1):18042. doi: 10.1038/s41598-018-36508-8.

9.

Selective agonist of TRPML2 reveals direct role in chemokine release from innate immune cells.

Plesch E, Chen CC, Butz E, Scotto Rosato A, Krogsaeter EK, Yinan H, Bartel K, Keller M, Robaa D, Teupser D, Holdt LM, Vollmar AM, Sippl W, Puertollano R, Medina D, Biel M, Wahl-Schott C, Bracher F, Grimm C.

Elife. 2018 Nov 27;7. pii: e39720. doi: 10.7554/eLife.39720.

10.

Transcriptional effects of actin-binding compounds: the cytoplasm sets the tone.

Gegenfurtner FA, Zisis T, Al Danaf N, Schrimpf W, Kliesmete Z, Ziegenhain C, Enard W, Kazmaier U, Lamb DC, Vollmar AM, Zahler S.

Cell Mol Life Sci. 2018 Dec;75(24):4539-4555. doi: 10.1007/s00018-018-2919-4. Epub 2018 Sep 11.

PMID:
30206640
11.

Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy.

Ardelt MA, Fröhlich T, Martini E, Müller M, Kanitz V, Atzberger C, Cantonati P, Meßner M, Posselt L, Lehr T, Wojtyniak JG, Ulrich M, Arnold GJ, König L, Parazzoli D, Zahler S, Rothenfußer S, Mayr D, Gerbes A, Scita G, Vollmar AM, Pachmayr J.

Hepatology. 2019 Jan;69(1):376-393. doi: 10.1002/hep.30190. Epub 2018 Dec 22.

12.

Micropatterning as a tool to identify regulatory triggers and kinetics of actin-mediated endothelial mechanosensing.

Gegenfurtner FA, Jahn B, Wagner H, Ziegenhain C, Enard W, Geistlinger L, Rädler JO, Vollmar AM, Zahler S.

J Cell Sci. 2018 May 29;131(10). pii: jcs212886. doi: 10.1242/jcs.212886.

13.

Endolysosomal Cation Channels and Cancer-A Link with Great Potential.

Grimm C, Bartel K, Vollmar AM, Biel M.

Pharmaceuticals (Basel). 2018 Jan 5;11(1). pii: E4. doi: 10.3390/ph11010004. Review.

14.

Persistent inhibition of pore-based cell migration by sub-toxic doses of miuraenamide, an actin filament stabilizer.

Moser C, Rüdiger D, Förster F, von Blume J, Yu P, Kuster B, Kazmaier U, Vollmar AM, Zahler S.

Sci Rep. 2017 Nov 27;7(1):16407. doi: 10.1038/s41598-017-16759-7.

15.

Data on chow, liver tissue and mitochondrial fatty acid compositions as well as mitochondrial proteome changes after feeding mice a western diet for 6-24 weeks.

Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H.

Data Brief. 2017 Sep 18;15:163-169. doi: 10.1016/j.dib.2017.09.019. eCollection 2017 Dec.

16.

Mitochondrial adaptation in steatotic mice.

Einer C, Hohenester S, Wimmer R, Wottke L, Artmann R, Schulz S, Gosmann C, Simmons A, Leitzinger C, Eberhagen C, Borchard S, Schmitt S, Hauck SM, von Toerne C, Jastroch M, Walheim E, Rust C, Gerbes AL, Popper B, Mayr D, Schnurr M, Vollmar AM, Denk G, Zischka H.

Mitochondrion. 2018 May;40:1-12. doi: 10.1016/j.mito.2017.08.015. Epub 2017 Sep 19.

PMID:
28935446
17.

TPC2 polymorphisms associated with a hair pigmentation phenotype in humans result in gain of channel function by independent mechanisms.

Chao YK, Schludi V, Chen CC, Butz E, Nguyen ONP, Müller M, Krüger J, Kammerbauer C, Ben-Johny M, Vollmar AM, Berking C, Biel M, Wahl-Schott CA, Grimm C.

Proc Natl Acad Sci U S A. 2017 Oct 10;114(41):E8595-E8602. doi: 10.1073/pnas.1705739114. Epub 2017 Sep 18.

18.

Inhibition of the V-ATPase by Archazolid A: A New Strategy to Inhibit EMT.

Merk H, Messer P, Ardelt MA, Lamb DC, Zahler S, Müller R, Vollmar AM, Pachmayr J.

Mol Cancer Ther. 2017 Nov;16(11):2329-2339. doi: 10.1158/1535-7163.MCT-17-0129. Epub 2017 Aug 3.

19.

Inhibition of Cdk5 induces cell death of tumor-initiating cells.

Mandl MM, Zhang S, Ulrich M, Schmoeckel E, Mayr D, Vollmar AM, Liebl J.

Br J Cancer. 2017 Mar 28;116(7):912-922. doi: 10.1038/bjc.2017.39. Epub 2017 Feb 21.

20.

Modulation of actin dynamics as potential macrophage subtype-targeting anti-tumour strategy.

Pergola C, Schubert K, Pace S, Ziereisen J, Nikels F, Scherer O, Hüttel S, Zahler S, Vollmar AM, Weinigel C, Rummler S, Müller R, Raasch M, Mosig A, Koeberle A, Werz O.

Sci Rep. 2017 Jan 30;7:41434. doi: 10.1038/srep41434.

21.

Two-Pore Channel Function Is Crucial for the Migration of Invasive Cancer Cells.

Nguyen ON, Grimm C, Schneider LS, Chao YK, Atzberger C, Bartel K, Watermann A, Ulrich M, Mayr D, Wahl-Schott C, Biel M, Vollmar AM.

Cancer Res. 2017 Mar 15;77(6):1427-1438. doi: 10.1158/0008-5472.CAN-16-0852. Epub 2017 Jan 20.

22.

A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic and Antileukemic Nature for Cancer Treatment.

Meier C, Steinhauer TN, Koczian F, Plitzko B, Jarolim K, Girreser U, Braig S, Marko D, Vollmar AM, Clement B.

ChemMedChem. 2017 Mar 7;12(5):347-352. doi: 10.1002/cmdc.201700026. Epub 2017 Feb 8.

PMID:
28099785
23.

V-ATPase inhibition increases cancer cell stiffness and blocks membrane related Ras signaling - a new option for HCC therapy.

Bartel K, Winzi M, Ulrich M, Koeberle A, Menche D, Werz O, Müller R, Guck J, Vollmar AM, von Schwarzenberg K.

Oncotarget. 2017 Feb 7;8(6):9476-9487. doi: 10.18632/oncotarget.14339.

24.

New View on Endothelial Cell Migration: Switching Modes of Migration Based on Matrix Composition.

Kick K, Nekolla K, Rehberg M, Vollmar AM, Zahler S.

Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2346-2357. Epub 2016 Oct 13.

PMID:
27737863
25.

Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.

Zhang S, Ulrich M, Gromnicka A, Havlíček L, Kryštof V, Jorda R, Strnad M, Vollmar AM, Zahler S.

Br J Pharmacol. 2016 Sep;173(17):2645-56. doi: 10.1111/bph.13546. Epub 2016 Jul 24.

26.

Contractility as a global regulator of cellular morphology, velocity, and directionality in low-adhesive fibrillary micro-environments.

Schuster SL, Segerer FJ, Gegenfurtner FA, Kick K, Schreiber C, Albert M, Vollmar AM, Rädler JO, Zahler S.

Biomaterials. 2016 Sep;102:137-47. doi: 10.1016/j.biomaterials.2016.06.021. Epub 2016 Jun 14.

PMID:
27336186
27.

Cyclin-dependent kinase 5 stabilizes hypoxia-inducible factor-1α: a novel approach for inhibiting angiogenesis in hepatocellular carcinoma.

Herzog J, Ehrlich SM, Pfitzer L, Liebl J, Fröhlich T, Arnold GJ, Mikulits W, Haider C, Vollmar AM, Zahler S.

Oncotarget. 2016 May 10;7(19):27108-21. doi: 10.18632/oncotarget.8342.

28.

Inhibition of endothelial Cdk5 reduces tumor growth by promoting non-productive angiogenesis.

Merk H, Zhang S, Lehr T, Müller C, Ulrich M, Bibb JA, Adams RH, Bracher F, Zahler S, Vollmar AM, Liebl J.

Oncotarget. 2016 Feb 2;7(5):6088-104. doi: 10.18632/oncotarget.6842.

29.

Actin-binding doliculide causes premature senescence in p53 wild type cells.

Foerster F, Chen T, Altmann KH, Vollmar AM.

Bioorg Med Chem. 2016 Jan 15;24(2):123-9. doi: 10.1016/j.bmc.2015.11.042. Epub 2015 Nov 30.

PMID:
26692350
30.

Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.

Zhang S, Schneider LS, Vick B, Grunert M, Jeremias I, Menche D, Müller R, Vollmar AM, Liebl J.

Oncotarget. 2015 Dec 22;6(41):43508-28. doi: 10.18632/oncotarget.6180.

31.

In vitro anti-cancer effects of the actin-binding natural compound rhizopodin.

Zhang S, Menche D, Zahler S, Vollmar AM, Liebl J, Förster F.

Pharmazie. 2015 Sep;70(9):610-5.

PMID:
26492647
32.

MOF nanoparticles coated by lipid bilayers and their uptake by cancer cells.

Wuttke S, Braig S, Preiß T, Zimpel A, Sicklinger J, Bellomo C, Rädler JO, Vollmar AM, Bein T.

Chem Commun (Camb). 2015 Nov 11;51(87):15752-5. doi: 10.1039/c5cc06767g.

PMID:
26359316
33.

Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2.

Liebl J, Zhang S, Moser M, Agalarov Y, Demir CS, Hager B, Bibb JA, Adams RH, Kiefer F, Miura N, Petrova TV, Vollmar AM, Zahler S.

Nat Commun. 2015 Jun 1;6:7274. doi: 10.1038/ncomms8274.

PMID:
26027726
34.

Vacuolar-ATPase Inhibition Blocks Iron Metabolism to Mediate Therapeutic Effects in Breast Cancer.

Schneider LS, von Schwarzenberg K, Lehr T, Ulrich M, Kubisch-Dohmen R, Liebl J, Trauner D, Menche D, Vollmar AM.

Cancer Res. 2015 Jul 15;75(14):2863-74. doi: 10.1158/0008-5472.CAN-14-2097. Epub 2015 May 27.

35.

Targeting cyclin dependent kinase 5 in hepatocellular carcinoma--A novel therapeutic approach.

Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM.

J Hepatol. 2015 Jul;63(1):102-13. doi: 10.1016/j.jhep.2015.01.031. Epub 2015 Feb 7.

PMID:
25660209
36.

The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility.

Menhofer MH, Kubisch R, Schreiner L, Zorn M, Foerster F, Mueller R, Raedler JO, Wagner E, Vollmar AM, Zahler S.

PLoS One. 2014 Nov 12;9(11):e112542. doi: 10.1371/journal.pone.0112542. eCollection 2014.

37.

A small molecule inhibits protein disulfide isomerase and triggers the chemosensitization of cancer cells.

Eirich J, Braig S, Schyschka L, Servatius P, Hoffmann J, Hecht S, Fulda S, Zahler S, Antes I, Kazmaier U, Sieber SA, Vollmar AM.

Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12960-5. doi: 10.1002/anie.201406577. Epub 2014 Sep 26.

PMID:
25256790
38.

In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor.

Menhofer MH, Bartel D, Liebl J, Kubisch R, Busse J, Wagner E, Müller R, Vollmar AM, Zahler S.

Cardiovasc Res. 2014 Nov 1;104(2):303-14. doi: 10.1093/cvr/cvu210. Epub 2014 Sep 19.

PMID:
25239826
39.

Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ.

Foerster F, Braig S, Moser C, Kubisch R, Busse J, Wagner E, Schmoeckel E, Mayr D, Schmitt S, Huettel S, Zischka H, Mueller R, Vollmar AM.

Cell Death Dis. 2014 Aug 28;5:e1398. doi: 10.1038/cddis.2014.363.

40.

The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer.

Braig S, Bischoff F, Abhari BA, Meijer L, Fulda S, Skaltsounis L, Vollmar AM.

Biochem Pharmacol. 2014 Sep 15;91(2):157-67. doi: 10.1016/j.bcp.2014.07.009. Epub 2014 Jul 25.

PMID:
25069048
41.

Pharmacological characterization of actin-binding (-)-doliculide.

Foerster F, Braig S, Chen T, Altmann KH, Vollmar AM.

Bioorg Med Chem. 2014 Sep 15;22(18):5117-22. doi: 10.1016/j.bmc.2014.03.003. Epub 2014 Mar 15.

PMID:
24679674
42.

V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells.

Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, Müller R, Wagner E, Vollmar AM.

Mol Cancer Ther. 2014 Apr;13(4):926-37. doi: 10.1158/1535-7163.MCT-13-0484. Epub 2014 Jan 30.

43.

Simplified pretubulysin derivatives and their biological effects on cancer cells.

Kubisch R, von Gamm M, Braig S, Ullrich A, Burkhart JL, Colling L, Hermann J, Scherer O, Müller R, Werz O, Kazmaier U, Vollmar AM.

J Nat Prod. 2014 Mar 28;77(3):536-42. doi: 10.1021/np4008014. Epub 2014 Jan 17.

PMID:
24437936
44.

Pretubulysin: a new option for the treatment of metastatic cancer.

Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, Fulda S, Vollmar AM.

Cell Death Dis. 2014 Jan 16;5:e1001. doi: 10.1038/cddis.2013.510.

45.

A novel role for inhibitor of apoptosis (IAP) proteins as regulators of endothelial barrier function by mediating RhoA activation.

Hornburger MC, Mayer BA, Leonhardt S, Willer EA, Zahler S, Beyerle A, Rajalingam K, Vollmar AM, Fürst R.

FASEB J. 2014 Apr;28(4):1938-46. doi: 10.1096/fj.13-235754. Epub 2013 Dec 26.

PMID:
24371121
46.

Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo.

Kretzschmann VK, Gellrich D, Ullrich A, Zahler S, Vollmar AM, Kazmaier U, Fürst R.

Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):294-303. doi: 10.1161/ATVBAHA.113.302155. Epub 2013 Nov 27.

PMID:
24285578
47.

Regulation of endothelial signaling and migration by v-ATPase.

Rath S, Liebl J, Fürst R, Vollmar AM, Zahler S.

Angiogenesis. 2014 Jul;17(3):587-601. doi: 10.1007/s10456-013-9408-z. Epub 2013 Nov 20.

PMID:
24254321
48.

V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo.

Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E.

Int J Cancer. 2014 May 15;134(10):2478-88. doi: 10.1002/ijc.28562. Epub 2013 Nov 14.

49.

V-ATPase inhibition overcomes trastuzumab resistance in breast cancer.

von Schwarzenberg K, Lajtos T, Simon L, Müller R, Vereb G, Vollmar AM.

Mol Oncol. 2014 Feb;8(1):9-19. doi: 10.1016/j.molonc.2013.08.011. Epub 2013 Sep 5.

50.

Indirubin derivative 6BIO suppresses metastasis.

Braig S, Kressirer CA, Liebl J, Bischoff F, Zahler S, Meijer L, Vollmar AM.

Cancer Res. 2013 Oct 1;73(19):6004-12. doi: 10.1158/0008-5472.CAN-12-4358. Epub 2013 Aug 14.

Supplemental Content

Loading ...
Support Center